SPTSSB

Serine palmitoyltransferase small subunit B · Q8NFR3 · SPTSSB on Sugi Atlas →

831 patent compounds predicted against SPTSSB, 677 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Gambogic Acid (SCHEMBL134152)	1.00	1/20
Gambogic Acid (SCHEMBL149213)	1.00	1/20
Gambogic Acid (SCHEMBL3857525)	1.00	1/20
Gambogic Acid (SCHEMBL7946944)	1.00	1/20
Gambogic Acid (SCHEMBL7947021)	1.00	1/20
Gambogic Acid (SCHEMBL12025351)	1.00	1/20
Gambogic Acid (SCHEMBL12025387)	1.00	1/20
Gambogic Acid (SCHEMBL12025441)	1.00	1/20
Gambogic Acid (SCHEMBL12026374)	1.00	1/20
Gambogic Acid (SCHEMBL12045553)	1.00	1/20
Gambogic Acid (SCHEMBL12045554)	1.00	1/20
Gambogic Acid (SCHEMBL12751296)	1.00	1/20
Gambogic Acid (SCHEMBL12859660)	1.00	1/20
Gambogic Acid (SCHEMBL13613351)	1.00	1/20
Gambogic Acid (SCHEMBL13685811)	1.00	1/20
Gambogic Acid (SCHEMBL13685812)	1.00	1/20
Gambogic Acid (SCHEMBL16160279)	1.00	1/20
Gambogic Acid (SCHEMBL1150670)	0.93	1/20
Gambogic Amide (SCHEMBL12751295)	0.89	1/20
Gambogic Amide (SCHEMBL15150010)	0.89	1/20

Clinical trials — most relevant to SPTSSB by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Cystagon to Treat Infantile Neuronal Ceroid Lipofuscinosis	PHASE4	COMPLETED
Effects of Botulinum Toxin Injections in Patients With Hereditary Spastic Paraplegia	PHASE2/PHASE3	COMPLETED
Hereditary Sensory Neuropathy Serine Trial	PHASE2	UNKNOWN
Anti-inflammatory Pulmonal Therapy of Cystic Fibrosis (CF) Patients With Amitriptyline and Placebo	PHASE2	UNKNOWN
Anti-Inflammatory Pulmonal Therapy of CF-Patients With Amitriptyline and Placebo	PHASE2	COMPLETED
Choline Effects - Pre-symptomatic AD	PHASE1	COMPLETED
Development of Biomarker for Development of Non-Alcoholic Steatohepatitis (NASH) in Children	nan	WITHDRAWN
Hydroxychloroquin (HCQ) in chILD of Genetic Defect	nan	COMPLETED
Targeting zDHHC Enzymes to Counteract Alzheimer's Disease	nan	NOT_YET_RECRUITING
Surfactant Derived Protocol in Heart Failure	nan	COMPLETED
Influence of WNT4 VEZT FSHB and SIRT1 SNPs in Endometriosis: a Case Control Study of the Sardinian Population	nan	UNKNOWN
Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia	nan	UNKNOWN
Sphingo-lipotoxicity and Trans-differentiation of Adipose Tissue in Obesity (SFINGOTRANS)	nan	COMPLETED
Evaluating the Association Between Sphingolipid Metabolites and Post-hepatectomy Liver Failure	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Thermogenic Silencer Regulatory Factors in Humans	nan	ACTIVE_NOT_RECRUITING
Screening of Healthy Adults for Genetic Variations That Control Fatty Acid Processing	nan	COMPLETED
HYPOCHOL : A Genetically-based Strategy to Identify New Targets in Cholesterol Metabolism	nan	ACTIVE_NOT_RECRUITING
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes	nan	COMPLETED
Epidemiology of Atherosclerosis	nan	COMPLETED
The ASTERS Study: Assessing the Role of Sphingolipids in AcuTE Respiratory Distress Syndrome (ARDS)	nan	COMPLETED
Protein Synthesis in the Brain of Patients With Fragile X Syndrome	nan	COMPLETED
Genetic Regulation of Surfactant Deficiency	nan	COMPLETED
Immune Cell Response to Stimuli	nan	RECRUITING
Gene Expression in Obesity and Insulin Resistance	nan	COMPLETED
EPICO: (Study for the Pro-resolution of Chronic Inflammation in Obesity. Original Acronym From Spanish)	nan	UNKNOWN
the Role of plin5 in the Development of Nonalcoholic Fatty Liver Disease.	nan	UNKNOWN
Fatty Acid Metabolism and Insulin Sensitivity: the Role of Endurance Exercise	nan	COMPLETED
Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study	nan	COMPLETED
Vulvodynia: Identification of Potential Relevant Biomarkers	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a SPTSSB binder may also engage these)

Protein	Name	Similarity
Q0IIK4	—	1.000	Q0IIK4 →
Q925E8	—	1.000	Q925E8 →
B9EN89	—	0.976	B9EN89 →
Q6DFT6	—	0.960	Q6DFT6 →
Q6GPZ5	—	0.957	Q6GPZ5 →
Q66J44	—	0.956	Q66J44 →
Q66J05	—	0.954	Q66J05 →
B0S4Q1	—	0.952	B0S4Q1 →
Q66H21	—	0.924	Q66H21 →
Q8WUD6	—	0.924	Q8WUD6 →
Q1LZE6	—	0.924	Q1LZE6 →
Q811P0	—	0.923	Q811P0 →
Q3SWT5	—	0.923	Q3SWT5 →
A5PMW0	—	0.922	A5PMW0 →
Q0VFH9	—	0.922	Q0VFH9 →
P86044	—	0.921	P86044 →
Q9M392	—	0.921	Q9M392 →
Q4KL91	—	0.921	Q4KL91 →
Q8C025	—	0.921	Q8C025 →
Q921R8	—	0.921	Q921R8 →
Q66KZ9	—	0.921	Q66KZ9 →
Q8R455	—	0.919	Q8R455 →
TRPM8	Transient receptor potential cation channel subfamily M member 8	0.918	landscape →
A4IH46	—	0.917	A4IH46 →
Q8N8D7	—	0.917	Q8N8D7 →
Q9FVQ5	—	0.917	Q9FVQ5 →
Q0III2	—	0.917	Q0III2 →
Q7ZX75	—	0.917	Q7ZX75 →
Q8VZM5	—	0.917	Q8VZM5 →
S5UH55	—	0.917	S5UH55 →